Filing Flows › Adma Biologics (ADMA) › Q2 2026
Adma Biologics (ADMA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Adma Biologics (ADMA) reported revenue of $124M for the second quarter 2026 (Q2 2026), +2% from a year earlier and +9% from the quarter before. Operating margin was 42.2%, net earnings $37.8M (30.4% of revenue).
Adma Biologics, Q2 2026: revenue $124M (+2% year over year), operating margin 42.2%, net earnings $37.8M, operating cash flow $29.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $124M | +9% | +2% |
| Gross profit | $86.3M | +7% | +28% |
| Operating profit | $52.4M | -10% | +23% |
| Net earnings | $37.8M | -17% | +11% |
| Operating cash flow | $29.5M | -49% | +40% |
| Free cash flow | $27.3M | -51% | +46% |
What changed
Revenue was $124.4M in Q2 2026, up 2% year over year and up 9% from the previous quarter. ADMABio Manufacturing Segment was the largest line at 99% of revenue. ADMABio Manufacturing Segment added $1.7M year over year (up 1%), 70% of the total change.
Gross margin was 69.4%, up 14.2 points from Q2 2025. Operating profit was $52.4M, a 42.2% margin (up 7.1 points year over year). Of the extra revenue versus Q2 2025, 400% reached operating profit, above the 35% margin then. Operating expenses grew 38% against revenue growth of 2%. The fastest-growing cost line was Research & development (+483%). Net earnings were $37.8M, up 11% year over year. The effective tax rate was 24.7%.
Operating cash flow was $29.5M (up 40% year over year), 78% of net earnings. Non-cash charges added back $1.7M of depreciation and amortization and $6.1M of share-based compensation. Working capital and other items used $16.1M. Capital expenditures of $2.3M left free cash flow of $27.3M.
Questions
What was Adma Biologics' revenue in the second quarter 2026?
Adma Biologics (ADMA) reported revenue of $124M for the second quarter 2026 (Q2 2026), +2% from a year earlier and +9% from the quarter before.
Was Adma Biologics profitable in the second quarter 2026?
Operating profit was $52.4M (42.2% of revenue) and net earnings $37.8M.
Source: Adma Biologics 10-Q on SEC EDGAR.